Commonwealth Retirement Investments LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 6,146 shares of the company’s stock, valued at approximately $521,000.
A number of other large investors also recently made changes to their positions in the company. O Shaughnessy Asset Management LLC lifted its position in shares of iShares U.S. Pharmaceuticals ETF by 35.0% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 463 shares of the company’s stock valued at $39,000 after purchasing an additional 120 shares in the last quarter. National Bank of Canada FI lifted its position in shares of iShares U.S. Pharmaceuticals ETF by 42.7% during the third quarter. National Bank of Canada FI now owns 585 shares of the company’s stock valued at $42,000 after purchasing an additional 175 shares in the last quarter. NBC Securities Inc. lifted its position in shares of iShares U.S. Pharmaceuticals ETF by 46.5% during the fourth quarter. NBC Securities Inc. now owns 630 shares of the company’s stock valued at $53,000 after purchasing an additional 200 shares in the last quarter. U.S. Capital Wealth Advisors LLC lifted its position in shares of iShares U.S. Pharmaceuticals ETF by 2.8% during the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 7,608 shares of the company’s stock valued at $645,000 after purchasing an additional 204 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC lifted its position in shares of iShares U.S. Pharmaceuticals ETF by 4.4% during the third quarter. Wealthcare Advisory Partners LLC now owns 5,115 shares of the company’s stock valued at $371,000 after purchasing an additional 217 shares in the last quarter.
iShares U.S. Pharmaceuticals ETF Price Performance
IHE opened at $92.59 on Tuesday. The company’s 50-day moving average is $88.39 and its 200 day moving average is $87.21. iShares U.S. Pharmaceuticals ETF has a fifty-two week low of $64.46 and a fifty-two week high of $94.23. The firm has a market capitalization of $999.97 million, a P/E ratio of 17.75 and a beta of 0.50.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Articles
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
